Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $50 and keeps an Overweight rating on the shares. The firm highlights potential upside on Phase 2 readout from the company’s CF program in mid-2025, where its expects positive efficacy and differentiated safety.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
- Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
- Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord
- Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue